Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Gall Bladder Cancer

Clinical Trial at: Medical Oncology Hematology Consultants - Newark

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4701 Ogletown-Stanton Road, Suite 3400
Newark, DE 19713
P: (302) 366-1200

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Virginia Oncology Associates - Newport News

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1051 Loftis Blvd, Suite 100
Newport News, VA 23606
P: (757) 873-9400

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Illinois Cancer Specialists - Niles

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

8915 W Golf Road
Niles, IL 60714
P: (847) 827-9060

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Odessa

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

500 W 3rd St
Odessa, TX 79761
P: (432) 335-8275

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Longview

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1300 North 4th Street
Longview, TX 75601
P: (903) 757-2122

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Minnesota Oncology - Maplewood

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

1580 Beam Avenue
Maplewood, MN 55109
P: (651) 779-7978

More Details View Practice Page
1 4 5 6 7 8 15